NCT02680574COMPLETEDanonymous

Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Vadadustat

Indication / condition

AI-normalized

Anemia

Intervention

Source record

Vadadustat, Darbepoetin alfa

Related intelligence directories

Indication directory: Anemia Modality directory: small molecule Target directory: Vadadustat

Source & freshness

Source record

NCT ID

NCT02680574

Original source

ClinicalTrials.gov

Source last updated

Jun 27, 2022

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02680574

Title

Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)

Sponsor

Akebia Therapeutics

Status

COMPLETED

Phase

Phase 3

Condition raw

Anemia

Condition normalized

Anemia

Modality raw

Anemia

Modality normalized

small molecule

Target raw

Vadadustat

Target normalized

Vadadustat

Interventions

Vadadustat, Darbepoetin alfa

Public preview

Source record

The clinical trial evaluated the efficacy and safety of Vadadustat for maintaining hemoglobin levels in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Conducted by Akebia Therapeutics, the study involved 1,725 participants and compared Vadadustat to Darbepoetin alfa, a standard treatment.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

Investment-Ready Snapshot

Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)

Source & freshness

Public preview

Create an account to unlock this report

Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)

Investment-Ready Snapshot

Provenance

Protocol Description

Outcome Measures

Eligibility

Known Results And Readout Context

Patent And IP Landscape

Contacts